A world-first partnership between industry, researchers and end users to transform antimicrobial resistance (AMR) and stewardship.
Antimicrobial resistance (AMR)…
… occurs when pathogens, such as bacteria and fungi, no longer respond to drugs that are intended to kill them.
AMR is one of the greatest scientific challenges of the 21st Century, and requires urgent investment to develop low-cost, implementable technologies capable of slowing the global emergence of AMR.
Sexually transmitted bacteria…
… are an exemplar of the wider, global problem of antimicrobial resistance and is a critical area of concern in relation to AMR.
microbiology, pharmacology, clinical, molecular biology, social sciences, disease modelling, health economics from research, industry, and end-users will develop a holistic approach to tackling the global AMR problem.
The Hub leverages substantive national and international investment and will deliver social, economic and commercial outcomes.
The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users.
The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR.
A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.
The Hub research plan is designed to address the health development threat of antimicrobial resistance (AMR) which the World Health Organization (WHO) has declared is one of the top 10 global public health threats facing humanity. As recommended by WHO, the Hub has established a multisectoral approach across Themes addressing antibacterial stewardship (social sciences), health economics, novel diagnostics (incorporating resistance guided therapy) and optimisation of sexually transmitted infection (STI) treatments.
Developing novel diagnostics to determine AMR status in real-time
Optimising STI treatments
Developing novel diagnostics to determine the presence of active bacterial infections
Engaging Stakeholders to Optimise AMR Innovation
The ARC ITRP Hub to Combat Antimicrobial Resistance is funded by the Australian Government through the Australian Research Council.